Patient demographics were comparable across study cohorts
From 22 January 2018 to 30 October 2020, a total of 122 patients from 18 sites in five countries were enrolled and randomized 2:1 to receive either motixafortide + G-CSF (80 patients) or placebo + G-CSF (42 patients) for HSPC mobilization (Fig. 